Michael Rome Ph.D

Michael Rome Ph.D General Information

Biography

Dr. Michael Rome serves as Board Member and Observer at Alumis. Dr. Michael Rome serves as Managing Director at Foresite Capital Management. He serves as Board Member at Candid Therapeutics, ReMix Therapeutics and Theseus Pharmaceuticals. He joined Foresite Capital in 2016 and is active in the firm's private and public market investments. He served as Board Member at Maze Therapeutics. He serves as Board Member at Avenzo Therapeutics. He was a board director at Kinnate Biopharma with board observer roles (past and present) at Turning Point Therapeutics, PACT Pharma, and Nurix Therapeutics. He has also led/co-led investments in several public companies across the Foresite portfolio. Prior to Foresite Capital, he was an analyst at DAFNA Capital Management, covering and formulating investment ideas for small/mid-cap biotech companies. He previously worked in early-stage drug development for an academic start-up out of the California NanoSystems Institute at UCLA. He received his Ph.D. in Biochemistry from Caltech as an NSF graduate research fellow and his B.S. in Molecular, Cell, and Developmental Biology from UCLA. He has more than 12 years of experience as a research scientist and has authored numerous publications in biomedical research journals. He served as Board Member at Pharvaris. He serves as Board Member at Esker Therapeutics, He served as Board Member at XinThera.